Scion Life Sciences’ Post

The most recent analysis conducted by our Biotechgate analysts about #Biotech #financings shows that, with the conclusion of the second quarter in 2023, investment activity has still failed to reach the heights of 2020 and 2021. June saw total funding in the US and Europe in the #privateequity market drop, while the rest of the regions around the globe increased from USD 100m in May to USD 315m. ITM Isotope Technologies Munich SE had the largest financing round in June and one of the largest private investment rounds in Europe to date, raising USD 274m. Read more: https://lnkd.in/dVnfPaX

Uncover investment opportunities in potential winners with the Next Edge Biotech and Life Sciences Opportunities Fund. With a unique investment approach, we offer exclusive access to small and midcap companies poised for growth. Click here and learn more about The Next Edge Biotech and Life Sciences Opportunities Fund: https://lnkd.in/eEsJKHt #AlternativeInvestments #NextEdgeCapital #Biotech #LifeSciences Eden Rahim Evie Dargel Braydon Evans Karl Bruce Janine Breck Richard Goode

What are BioTech ETFs and should you consider investing? Investing in biotech ETFs can be a way to participate in the potential growth and innovation of the sector while managing some of the associated risks through diversification. However, due to the sector's inherent volatility and specific challenges, it's important to conduct thorough research. This article looks at some pros and cons: https://bit.ly/3Rzji0J If you're thinking about entering the BioTech industry, our experienced team can help to advise you. Get in touch today: https://bit.ly/2XhmYdS #BioTech #Investment #ETF #Diversification

Market Insights: Last Week’s Top Performers!🚀 In our latest analysis, we spotlight the five standout performers from our recommendations, featuring impressive gains from four junior resource companies and one leading biotech firm. Check out the full list: https://lnkd.in/gaJgJp3c #Investing #ResourceCompanies #Biotech #MarketLeaders #InvestmentInsights

Aplantex is pleased to announce the arrival of Frederick Perrault, CPA,CA,MSc, as lead investor, strategic advisor, and member of the company’s Board of directors. His valuable contribution will help us make informed decisions, strengthen our governance, and refine our strategies in the context of a dynamic competitive landscape and thus reach our full potential. 2024 is a pivotal year for Aplantex as we are firing up commercialization. Navigating those challenging waters with Frederick at our side will maximize our ability to reach our objectives. #governancematters #financeleadership #growth #vcfunding #institutionalinvestors #mentorship #biotechnology #esgsolutions  #circulareconomy  #innovation  #sustainability  #pharmaceuticalindustry  #cosmeticsindustry #foodandbeverageindustry

What will #biotech #venturecapital look like in 2024? Several experts on a #BiotechShowcase panel in San Francisco expressed positive attitudes for the coming year. https://lnkd.in/gaSxxv5i #JPM2024 #JPM24 BioSpace #funding #biotechnology

What is key for navigating the investment ecosystem? Here are a few tips: Leverage partnerships so you can focus only on a few things, don't use venture dollars for CAPEX, e.g. building out facilities, make sure to play devil's advocate when developing a realistic MVP. Very insightful! #venturecapital #investing #synbio #syntheticbiology #synbiobeta #synbiobeta2024

Roop Chandwani and Piers Morgan sit down for an honest chat about where #biotech #investment is heading next. Let us know what you think below. See the full video: https://pst.bz/GD2UIZ3 #precisionexecutivesearch #lifescience #investors #venturecapital #privateequity  Rory Lavelle Aamir Butt Tom Treherne Devin Welch

Several experts on a panel Wednesday at JPM's Biotech Showcase expressed positive attitudes for the coming year on the investment side. 🗨️ "What's exciting is despite the hard times in 2023 . . . the last two months of the year have been quite productive, November and December," noted panelist Maha Katabi, general partner at Sofinnova Investments. "We closed the year with 23 M&A deals in the industry. . . . And the last time we exceeded that number was . . . in 2002." Read the advice panelists had for companies on navigating the coming year below ⤵️ #JPM #Biotech #Investments